Establishing a comprehensive panel of patient-derived xenograft models for high-grade endometrial carcinoma: molecular subtypes, genetic alterations, and therapeutic target profiling
The molecularly classified EC-PDX panel, enriched with detailed antigen profiles and genetic data, provides a robust platform for investigating novel ADC therapies and precision treatment strategies for high-grade EC.
Authors
- Tadaaki Nishikawa (ORCID: https://orcid.org/0000-0003-2606-4208)
- Shigehiro Yagishita (ORCID: https://orcid.org/0000-0002-1277-1203)
- Keiji Furuuchi (ORCID: https://orcid.org/0000-0002-2810-6283)
- Masanori Yasuda (ORCID: https://orcid.org/0000-0002-0769-360X)
- Hiroshi Yoshida (ORCID: https://orcid.org/0000-0002-7569-7813)
- Toshimitsu Uenaka (ORCID: https://orcid.org/0009-0002-8573-9295)
- Akinobu Hamada (ORCID: https://orcid.org/0000-0002-3467-2644)
- Daisuke Shintani (ORCID: https://orcid.org/0000-0001-6689-8915)
- Aiko Ogasawara (ORCID: https://orcid.org/0000-0001-7752-293X)
- Kosei Hasegawa (ORCID: https://orcid.org/0000-0002-1903-7001)
- Sho Sato (ORCID: https://orcid.org/0000-0001-5628-7141)
Institutions
- Precision Therapeutics (United States) (US)
- Saitama International Medical Center (JP)
- Tokyo National Hospital (JP)
- National Cancer Research Institute (GB)
- Saitama Medical University (JP)
Publication Details
- Journal
- Neoplasia
- Published
- 2025-04-08
- DOI
- https://doi.org/10.1016/j.neo.2025.101158
- Citations
- 2
- Primary Topic
- Endometrial and Cervical Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 4.11
Funders
- National Cancer Center
- National Cancer Center Japan
- Eisai